DXM + Salvinorin A (Salvia divinorum)

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 1 to 3

https://dxm-atlas.org/en/interactions/salvinorin-a/

Compare

Key points for this combination

Specific toxic synergy not established. Functional impairment and secondary physical hazards [17]

How well is this understood?

Mechanism confidence: medium

Confidence in the mechanism: medium

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Confidence in human DXM data: low

Confidence in direct human evidence involving DXM: low

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method

How to read ratings and study limits

How do the substances interact?

How can the effects add up?

Mechanism: KOR — κ-opioid effects
ⓘ

KOR — κ-opioid receptor

One type of opioid receptor.

κ and μ are labels for different types of opioid receptor.

Sources: KOR — κ-opioid receptor
Mechanism: IMP — Functional impairment
ⓘ

Cannabinoid-related effects / functional impairment and secondary physical hazards

Synergy

A combined effect that is stronger than expected from additivity.

Synergy is assessed by comparing the measured combined effect with the result predicted from the substances’ separate actions. The comparison uses a specified effect and a chosen model of additivity.

Sources: Synergy

In the glossary

Sources

Check the review’s wording

Specific toxic synergy not established; functional impairment and secondary physical hazards [17]

What was studied for salvinorin A

Controlled studies of salvinorin A alone found relatively stable physiological measures under the studied conditions; they did not examine DXM. Salvinorin acts through a κ-opioid mechanism. Its pharmacology differs from the μ-opioid mechanism of fentanyl’s respiratory effects [17].

Read the full passage

Combination row in the review: KOR — κ-opioid effects; IMP — Functional impairment

Related entries

Reference

Open the source and related combinations →